Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2,2-Difluoroethanaminium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,2-Difluoroethanaminium SCHEMBL25759 | 0.95 | — | — | |
| 2,2-Difluoroethanaminium SCHEMBL28105969 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL9847517 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL31268132 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL25214533 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL11635122 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL16395482 | 0.73 | — | — | |
| 2,2-Difluoroethanaminium SCHEMBL1445565 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL18226426 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL15635390 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276315-A | Preparation method of 4- [4- [4- (4-hydroxyphenyl) piperazine-1-yl ] phenyl carbamate | 苏州汉德创宏生化科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3697860-A2 | SURFACE TREATMENT | Interphase Materials Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| US-20200231842-A1 | Surface Treatment | INTERPHASE MAT INC (US) | 2020-07-23 | — | — | US | claimed |
| WO-2019164546-A2 | SURFACE TREATMENT | INTERPHASE MATERIALS INC. (US) | 2019-08-29 | — | — | WO | claimed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025215558-A1 | COMPOUNDS FOR SPLICING MODULATION | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-10-16 | — | — | WO | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| CN-114072393-B | 3-Amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors | 索伦特治疗有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12304910-B2 | Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-6323343-B1 | REACING 8-(HALOUOROETHYL)-8-AZABICYCLO(3.2.1)OCTAN-3-ONE WITH ALKALI METAL CYANIDE IN PRESENCE OF ACID AND BASE, 3-CYANO-3-HYDROXY-8-(2,2,2-TRIFLUOROETHYL)-8-AZABICYCLO(3.2.1) OCTANE | SYNGENTA LIMITED (GB) | 2001-11-27 | — | — | US | disclosed |
| CN-1281456-A | Process for the preparation of 8-azabicyclo [3.2.1] octane derivatives | ZENECA LTD (GB) | 2001-01-24 | — | — | CN | disclosed |
| EP-1051417-A1 | PROCESS FOR THE PREPARATION OF 8-AZABICYCLO(3.2.1)OCTANE DERIVATIVES | ZENECA LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999029690-A1 | PROCESS FOR THE PREPARATION OF 8-AZABICYCLO(3.2.1)OCTANE DERIVATIVES | ZENECA LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| US-4762932-A | Haloguanidine intermediates | IMPERIAL CHEMICAL INDUSTRIES, LTD. (GB) | 1988-08-09 | — | — | US | disclosed |
| US-4604465-A | Haloguanidine intermediates | ICI AMERICAS, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4362728-A | Haloguanidine compounds, pharmaceutical compositions and methods of use | ICI AMERICAS INC. (US) | 1982-12-07 | — | — | US | disclosed |
| EP-0030092-A1 | Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-06-10 | — | — | EP | disclosed |